AF
SLDB icon

Amalgamated Financial’s Solid Biosciences SLDB Stock Holding History

Amalgamated Financial’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9K Buy
+479
New +$8.45K ﹤0.01% 2914

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Amalgamated Financial's SLDB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Solid Biosciences (SLDB) in Q1 2022: 479 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2914 among its holdings.

77 funds tracked by Wall St. Rank hold SLDB as of Q1 2022.

  • Amalgamated Financial held 479 shares of Solid Biosciences worth $9K as of Q1 2022.
  • Solid Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Solid Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2914 holding.
  • 77 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.